Celcuity (NASDAQ:CELC) Shares Up 6.7% – Time to Buy?

Celcuity, Inc. (NASDAQ:CELC)’s stock price shot up 6.7% during mid-day trading on Tuesday . The company traded as high as $115.84 and last traded at $115.8650. Approximately 716,307 shares traded hands during mid-day trading, a decline of 30% from the average session volume of 1,022,356 shares. The stock had previously closed at $108.58.

Analysts Set New Price Targets

A number of brokerages have weighed in on CELC. Leerink Partners set a $155.00 price objective on Celcuity in a report on Tuesday, June 2nd. Stifel Nicolaus set a $150.00 price target on shares of Celcuity in a research report on Monday, May 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $157.00 price objective on shares of Celcuity in a research note on Friday, May 15th. Wells Fargo & Company decreased their target price on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Finally, Craig Hallum dropped their price target on Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Celcuity currently has a consensus rating of “Moderate Buy” and an average target price of $152.09.

Celcuity Trading Up 3.1%

The stock has a market cap of $5.47 billion, a PE ratio of -28.82 and a beta of 0.16. The company’s 50-day moving average price is $112.16 and its 200 day moving average price is $110.93. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. On average, sell-side analysts forecast that Celcuity, Inc. will post -3.69 EPS for the current fiscal year.

Insider Buying and Selling at Celcuity

In other news, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the sale, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.33% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CELC. EverSource Wealth Advisors LLC increased its stake in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares during the period. US Bancorp DE increased its position in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares in the last quarter. Parallel Advisors LLC purchased a new position in Celcuity in the first quarter valued at $38,000. Finally, Meeder Asset Management Inc. acquired a new position in Celcuity during the 4th quarter worth $42,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.